Critically, since CETP inhibitors such as obicetrapib are currently in phase 3 clinical trials to treat dyslipidemia and coronary artery disease, its clean safety and toxicity profile makes it a good repurposing candidate for metabolic disease and combination therapies. The gene discussed is CETP; the disease is metabolic disease.